Phenytoin

Last updated

Phenytoin
Phenytoin structure.svg
Phenytoin 3D ball.png
Clinical data
Pronunciation /fəˈnɪtoʊɪn,ˈfɛnɪtɔɪn/
Trade names Dilantin, others [1]
AHFS/Drugs.com Monograph
MedlinePlus a682022
License data
Pregnancy
category
  • AU:D
  • Toxic to reproduction
Routes of
administration 		By mouth, intravenous
Drug class Anticonvulsant
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 70–100% (oral), 24.4% (rectal)
Protein binding 95% [3]
Metabolism Liver
Onset of action 10–30 min (intravenous) [4]
Elimination half-life 10–22 hours [3]
Duration of action 24 hours [4]
Excretion Urinary (23–70%), bile [5]
Identifiers
  • 5,5-diphenylimidazolidine-2,4-dione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.000.298 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C15H12N2O2
Molar mass 252.273 g·mol−1
3D model (JSmol)
  • C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3
  • InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19) X mark.svgN
  • Key:CXOFVDLJLONNDW-UHFFFAOYSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Phenytoin (PHT), sold under the brand name Dilantin among others, [1] is an anti-seizure medication. [3] It is useful for the prevention of tonic-clonic seizures (also known as grand mal seizures) and focal seizures, but not absence seizures. [3] The intravenous form, fosphenytoin, is used for status epilepticus that does not improve with benzodiazepines. [3] It may also be used for certain heart arrhythmias or neuropathic pain. [3] It can be taken intravenously or by mouth. [3] The intravenous form generally begins working within 30 minutes and is effective for roughly 24 hours. [4] Blood levels can be measured to determine the proper dose. [3]

Contents

Common side effects include nausea, stomach pain, loss of appetite, poor coordination, increased hair growth, and enlargement of the gums. [3] Potentially serious side effects include sleepiness, self harm, liver problems, bone marrow suppression, low blood pressure, and toxic epidermal necrolysis. [3] There is evidence that use during pregnancy results in abnormalities in the baby. [3] It appears to be safe to use when breastfeeding. [3] Alcohol may interfere with the medication's effects. [3]

Phenytoin was first made in 1908 by the German chemist Heinrich Biltz and found useful for seizures in 1936. [6] [7] It is on the World Health Organization's List of Essential Medicines. [8] Phenytoin is available as a generic medication. [9] In 2020, it was the 260th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [10] [11]

Medical uses

Seizures

Though phenytoin has been used to treat seizures in infants, as of 2023, its effectiveness in this age group has been evaluated in only one study. Due to the lack of a comparison group, the evidence is inconclusive. [14]

Other

Special considerations

Side effects

Common side effects include nausea, stomach pain, loss of appetite, poor coordination, increased hair growth, and enlargement of the gums. Potentially serious side effects include sleepiness, self harm, liver problems, bone marrow suppression, low blood pressure, and toxic epidermal necrolysis. There is evidence that use during pregnancy results in abnormalities in the baby. Its use appears to be safe during breastfeeding.Alcohol may interfere with the medication's effects. [3]

Heart and blood vessels

Severe low blood pressure and abnormal heart rhythms can be seen with rapid infusion of IV phenytoin. IV infusion should not exceed 50 mg/min in adults or 1–3 mg/kg/min (or 50 mg/min, whichever is slower) in children. Heart monitoring should occur during and after IV infusion. Due to these risks, oral phenytoin should be used if possible. [18]

Neurological

At therapeutic doses, phenytoin may produce nystagmus on lateral gaze. At toxic doses, patients experience vertical nystagmus, double vision, sedation, slurred speech, cerebellar ataxia, and tremor. [19] If phenytoin is stopped abruptly, this may result in increased seizure frequency, including status epilepticus. [18] [17]

Phenytoin may accumulate in the cerebral cortex over long periods of time which can cause atrophy of the cerebellum. The degree of atrophy is related to the duration of phenytoin treatment and is not related to dosage of the medication. [20]

Phenytoin is known to be a causal factor in the development of peripheral neuropathy. [21]

Blood

Folate is present in food in a polyglutamate form, which is then converted into monoglutamates by intestinal conjugase to be absorbed by the jejunum. Phenytoin acts by inhibiting this enzyme, thereby causing folate deficiency, and thus megaloblastic anemia. [22] Other side effects may include: agranulocytosis, [23] aplastic anemia, [24] decreased white blood cell count, [25] and a low platelet count. [26]

Pregnancy

Phenytoin is a known teratogen, since children exposed to phenytoin are at a higher risk of birth defects than children born to women without epilepsy and to women with untreated epilepsy. [27] [28] The birth defects, which occur in approximately 6% of exposed children, include neural tube defects, heart defects and craniofacial abnormalities, including broad nasal bridge, cleft lip and palate, and smaller than normal head. [28] [29] The effect on IQ cannot be determined as no study involves phenytoin as monotherapy, however poorer language abilities and delayed motor development may have been associated with maternal use of phenytoin during pregnancy. [27] This syndrome resembles the well-described fetal alcohol syndrome. [30] and has been referred to as "fetal hydantoin syndrome". Some recommend avoiding polytherapy and maintaining the minimal dose possible during pregnancy, but acknowledge that current data fails to demonstrate a dose effect on the risk of birth defects. [27] [28] Data now being collected by the Epilepsy and Antiepileptic Drug Pregnancy Registry may one day answer this question definitively.

Cancer

There is no good evidence to suggest that phenytoin is a human carcinogen. [31] [32] However, lymph node abnormalities have been observed, including malignancies. [33]

Mouth

Phenytoin has been associated with drug-induced gingival enlargement (overgrowth of the gums), probably due to above-mentioned folate deficiency; indeed, evidence from a randomized controlled trial suggests that folic acid supplementation can prevent gingival enlargement in children who take phenytoin. [34] Plasma concentrations needed to induce gingival lesions have not been clearly defined. Effects consist of the following: bleeding upon probing, increased gingival exudate, pronounced gingival inflammatory response to plaque levels, associated in some instances with bone loss but without tooth detachment.

Skin

Hypertrichosis, Stevens–Johnson syndrome, purple glove syndrome, rash, exfoliative dermatitis, itching, excessive hairiness, and coarsening of facial features can be seen in those taking phenytoin.

Phenytoin therapy has been linked to the life-threatening skin reactions Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). These conditions are significantly more common in patients with a particular HLA-B allele, HLA-B*1502. [35] This allele occurs almost exclusively in patients with ancestry across broad areas of Asia, including South Asian Indians.

Phenytoin is primarily metabolized to its inactive form by the enzyme CYP2C9. Variations within the CYP2C9 gene that result in decreased enzymatic activity have been associated with increased phenytoin concentrations, as well as reports of drug toxicities due to these increased concentrations. [36] The U.S. Food and Drug Administration (FDA) notes on the phenytoin drug label that since strong evidence exists linking HLA-B*1502 with the risk of developing SJS or TEN in patients taking carbamazepine, consideration should be given to avoiding phenytoin as an alternative to carbamazepine in patients carrying this allele. [37]

Immune system

Phenytoin has been known to cause drug-induced lupus. [38]

Phenytoin is also associated with induction of reversible IgA deficiency. [39]

Psychological

Phenytoin may increase risk of suicidal thoughts or behavior. People on phenytoin should be monitored for any changes in mood, the development or worsening depression, and/or any thoughts or behavior of suicide. [17]

Bones

Chronic phenytoin use has been associated with decreased bone density and increased bone fractures. Phenytoin induces metabolizing enzymes in the liver. This leads to increased metabolism of vitamin D, thus decreased vitamin D levels. Vitamin D deficiency, as well as low calcium and phosphate in the blood cause decreased bone mineral density. [17]

Interactions

Phenytoin is an inducer of the CYP3A4 and CYP2C9 families of the P450 enzyme responsible for the liver's degradation of various drugs. [40]

A 1981 study by the National Institutes of Health showed that antacids administered concomitantly with phenytoin "altered not only the extent of absorption but also appeared to alter the rate of absorption. Antacids administered in a peptic ulcer regimen may decrease the AUC of a single dose of phenytoin. Patients should be cautioned against concomitant use of antacids and phenytoin." [41]

Warfarin and trimethoprim increase serum phenytoin levels and prolong the serum half-life of phenytoin by inhibiting its metabolism. Consider using other options if possible. [42]

In general, phenytoin can interact with the following drugs:

Pharmacology

Mechanism of action

The mechanism of action of phenytoin sodium. Sodium channels are: 1) Closed 2) Open 3) Inactive (phenytoin effect) Phenytoin sodium mechanism of action.png
The mechanism of action of phenytoin sodium. Sodium channels are: 1) Closed 2) Open 3) Inactive (phenytoin effect)

Phenytoin is believed to protect against seizures by causing voltage-dependent block of voltage gated sodium channels. [43] This blocks sustained high frequency repetitive firing of action potentials. This is accomplished by reducing the amplitude of sodium-dependent action potentials through enhancing steady-state inactivation. Sodium channels exist in three main conformations: the resting state, the open state, and the inactive state.

Phenytoin binds preferentially to the inactive form of the sodium channel. Because it takes time for the bound drug to dissassociate from the inactive channel, there is a time-dependent block of the channel. Since the fraction of inactive channels is increased by membrane depolarization as well as by repetitive firing, the binding to the inactive state by phenytoin sodium can produce voltage-dependent, use-dependent and time-dependent block of sodium-dependent action potentials. [44]

The primary site of action appears to be the motor cortex where spread of seizure activity is inhibited. [45] Possibly by promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of post-tetanic potentiation at synapses which prevents cortical seizure foci from detonating adjacent cortical areas. Phenytoin reduces the maximal activity of brain stem centers responsible for the tonic phase of generalized tonic-clonic seizures. [18]

Pharmacokinetics

Phenytoin elimination kinetics show mixed-order, non-linear elimination behaviour at therapeutic concentrations. Where phenytoin is at low concentration it is cleared by first order kinetics, and at high concentrations by zero order kinetics. A small increase in dose may lead to a large increase in drug concentration as elimination becomes saturated. The time to reach steady state is often longer than 2 weeks. [46] [47] [48] [49]

History

Phenytoin (diphenylhydantoin) was first synthesized by German chemist Heinrich Biltz in 1908. [50] Biltz sold his discovery to Parke-Davis, which did not find an immediate use for it. In 1938, other physicians, including H. Houston Merritt and Tracy Putnam, discovered phenytoin's usefulness for controlling seizures, without the sedative effects associated with phenobarbital. [51]

According to Goodman and Gilman's Pharmacological Basis of Therapeutics:

In contrast to the earlier accidental discovery of the antiseizure properties of potassium bromide and phenobarbital, phenytoin was the product of a search among nonsedative structural relatives of phenobarbital for agents capable of suppressing electroshock convulsions in laboratory animals. [52]

It was approved by the FDA in 1953 for use in seizures.

Jack Dreyfus, founder of the Dreyfus Fund, became a major proponent of phenytoin as a means to control nervousness and depression when he received a prescription for Dilantin in 1966. He has claimed to have supplied large amounts of the drug to Richard Nixon throughout the late 1960s and early 1970s, although this is disputed by former White House aides [53] and Presidential historians. [54] Dreyfus' experience with phenytoin is outlined in his book, A Remarkable Medicine Has Been Overlooked. [55] Despite more than $70 million in personal financing, his push to see phenytoin evaluated for alternative uses has had little lasting effect on the medical community. This was partially because Parke-Davis was reluctant to invest in a drug nearing the end of its patent life, and partially due to mixed results from various studies.

In 2008, the drug was put on the FDA's Potential Signals of Serious Risks List to be further evaluated for approval. The list identifies medications with which the FDA has identified potential safety issues, but has not yet identified a causal relationship between the drug and the listed risk. To address this concern, the Warnings and Precautions section of the labeling for Dilantin injection was updated to include additional information about Purple glove syndrome in November 2011. [56]

Society and culture

Economics

Phenytoin is available as a generic medication. [9]

Since September 2012, the marketing licence in the UK has been held by Flynn Pharma Ltd, of Dublin, Ireland, and the product, although identical, has been called Phenytoin Sodium xxmg Flynn Hard Capsules. (The xxmg in the name refers to the strength—for example "Phenytoin sodium 25 mg Flynn Hard Capsules"). [57] The capsules are still made by Pfizer's Goedecke subsidiary's plant in Freiburg, Germany, and they still have Epanutin printed on them. [58] After Pfizer's sale of the UK marketing licence to Flynn Pharma, the price of a 28-pack of 25 mg phenytoin sodium capsules marked Epanutin rose from 66p (about $0.88) to £15.74 (about $25.06). Capsules of other strengths also went up in price by the same factor—2,384%, [59] costing the UK's National Health Service an extra £43 million (about $68.44 million) a year. [60] The companies were referred to the Competition and Markets Authority (CMA) who found that they had exploited their dominant position in the market to charge "excessive and unfair" prices. [61]

The CMA imposed a record £84.2 million fine on the manufacturer Pfizer, and a £5.2 million fine on the distributor Flynn Pharma and ordered the companies to reduce their prices. [62]

Brand names

Phenytoin is marketed under many brand names worldwide. [1]

In the US, Dilantin is marketed by Viatris after Upjohn was spun off from Pfizer. [63] [64] [65]

Research

Tentative evidence suggests that topical phenytoin is useful in wound healing in people with chronic skin wounds. [66] [67] A meta-analysis also supported the use of phenytoin in managing various ulcers. [68] Phenytoin is incorporated into compounded medications to optimize wound treatment, often in combination with misoprostol. [69] [70]

Some clinical trials have explored whether phenytoin can be used as neuroprotector in multiple sclerosis. [71]

Related Research Articles

<span class="mw-page-title-main">Carbamazepine</span> Anticonvulsant medication

Carbamazepine, sold under the brand name Tegretol among others, is an anticonvulsant medication used in the treatment of epilepsy and neuropathic pain. It is used as an adjunctive treatment in schizophrenia along with other medications and as a second-line agent in bipolar disorder. Carbamazepine appears to work as well as phenytoin and valproate for focal and generalized seizures. It is not effective for absence or myoclonic seizures.

<span class="mw-page-title-main">Epilepsy</span> Group of neurological disorders causing seizures

Epilepsy is a group of non-communicable neurological disorders characterized by recurrent epileptic seizures. An epileptic seizure is the clinical manifestation of an abnormal, excessive, and synchronized electrical discharge in the neurons. The occurrence of two or more unprovoked seizures defines epilepsy. The occurrence of just one seizure may warrant the definition in a more clinical usage where recurrence may be able to be prejudged. Epileptic seizures can vary from brief and nearly undetectable periods to long periods of vigorous shaking due to abnormal electrical activity in the brain. These episodes can result in physical injuries, either directly, such as broken bones, or through causing accidents. In epilepsy, seizures tend to recur and may have no detectable underlying cause. Isolated seizures that are provoked by a specific cause such as poisoning are not deemed to represent epilepsy. People with epilepsy may be treated differently in various areas of the world and experience varying degrees of social stigma due to the alarming nature of their symptoms.

<span class="mw-page-title-main">Valproate</span> Medication used for epilepsy, bipolar disorder and migraine

Valproate are medications primarily used to treat epilepsy and bipolar disorder and prevent migraine headaches. They are useful for the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures. They can be given intravenously or by mouth, and the tablet forms exist in both long- and short-acting formulations.

Anticonvulsants are a diverse group of pharmacological agents used in the treatment of epileptic seizures. Anticonvulsants are also increasingly being used in the treatment of bipolar disorder and borderline personality disorder, since many seem to act as mood stabilizers, and for the treatment of neuropathic pain. Anticonvulsants suppress the excessive rapid firing of neurons during seizures. Anticonvulsants also prevent the spread of the seizure within the brain.

<span class="mw-page-title-main">Lorazepam</span> Benzodiazepine medication

Lorazepam, sold under the brand name Ativan among others, is a benzodiazepine medication. It is used to treat anxiety, trouble sleeping, severe agitation, active seizures including status epilepticus, alcohol withdrawal, and chemotherapy-induced nausea and vomiting. It is also used during surgery to interfere with memory formation and to sedate those who are being mechanically ventilated. It is also used, along with other treatments, for acute coronary syndrome due to cocaine use. It can be given orally, transdermal, intravenously (IV), or intramuscularly When given by injection, onset of effects is between one and thirty minutes and effects last for up to a day.

<span class="mw-page-title-main">Topiramate</span> Medication used to treat epilepsy and migraine

Topiramate, sold under the brand name Topamax among others, is a medication used to treat epilepsy and prevent migraines. It has also been used in alcohol dependence and essential tremor. For epilepsy this includes treatment for generalized or focal seizures. It is taken orally.

<span class="mw-page-title-main">Lamotrigine</span> Medication used for bipolar disorder, epilepsy, & many seizure disorders

Lamotrigine, sold under the brand name Lamictal among others, is a medication used to treat epilepsy and stabilize mood in bipolar disorder. For epilepsy, this includes focal seizures, tonic-clonic seizures, and seizures in Lennox-Gastaut syndrome. In bipolar disorder, lamotrigine has not been shown to reliably treat acute depression in any groups except for the severely depressed; but for patients with bipolar disorder who are not currently symptomatic, it appears to reduce the risk of future episodes of depression.

Absence seizures are one of several kinds of generalized seizures. In the past, absence epilepsy was referred to as "pyknolepsy," a term derived from the Greek word "pyknos," signifying "extremely frequent" or "grouped". These seizures are sometimes referred to as petit mal seizures ; however, usage of this terminology is no longer recommended. Absence seizures are characterized by a brief loss and return of consciousness, generally not followed by a period of lethargy. Absence seizures are most common in children. They affect both sides of the brain.

<span class="mw-page-title-main">Oxcarbazepine</span> Anticonvulsant medication

Oxcarbazepine, sold under the brand name Trileptal among others, is a medication used to treat epilepsy. For epilepsy it is used for both focal seizures and generalized seizures. It has been used both alone and as add-on therapy in people with bipolar disorder who have had no success with other treatments. It is taken by mouth.

<span class="mw-page-title-main">Levetiracetam</span> Medication

Levetiracetam, sold under the brand name Keppra among others, is a medication used to treat epilepsy. It is used for partial-onset, myoclonic, or tonic–clonic seizures and is taken either by mouth as an immediate or extended release formulation or by injection into a vein.

<span class="mw-page-title-main">Clonazepam</span> Benzodiazepine medication

Clonazepam, sold under the brand names Klonopin and Rivotril, is a medication used to prevent and treat anxiety disorders, seizures, bipolar mania, agitation associated with psychosis, OCD and akathisia. It is a long-acting tranquilizer of the benzodiazepine class. It possesses anxiolytic, anticonvulsant, sedative, hypnotic, and skeletal muscle relaxant properties. It is typically taken orally but is also used intravenously. Effects begin within one hour and last between eight and twelve hours in adults.

<span class="mw-page-title-main">Nitrazepam</span> Benzodiazepine sedative

Nitrazepam, sold under the brand name Mogadon among others, is a hypnotic drug of the benzodiazepine class used for short-term relief from severe, disabling anxiety and insomnia. It also has sedative (calming) properties, as well as amnestic, anticonvulsant, and skeletal muscle relaxant effects.

<span class="mw-page-title-main">Phenobarbital</span> Medication of the barbiturate type

Phenobarbital, also known as phenobarbitone or phenobarb, sold under the brand name Luminal among others, is a medication of the barbiturate type. It is recommended by the World Health Organization (WHO) for the treatment of certain types of epilepsy in developing countries. In the developed world, it is commonly used to treat seizures in young children, while other medications are generally used in older children and adults. It is also used for veterinary purposes. It may be used intravenously, injected into a muscle, or taken by mouth. The injectable form may be used to treat status epilepticus. Phenobarbital is occasionally used to treat trouble sleeping, anxiety, and drug withdrawal and to help with surgery. It usually begins working within five minutes when used intravenously and half an hour when administered by mouth. Its effects last for between four hours and two days.

<span class="mw-page-title-main">Primidone</span> Barbiturate medication used to treat seizures and tremors

Primidone, sold under various brand names, is a barbiturate medication that is used to treat partial and generalized seizures and essential tremors. It is taken by mouth.

<span class="mw-page-title-main">Vigabatrin</span> Epilepsy medication

Vigabatrin, sold under the brand names Vigafyde, Vigpoder and Sabril among others, is a medication used in the management and treatment of infantile spasms and refractory complex partial seizures.

<span class="mw-page-title-main">Clobazam</span> Benzodiazepine class medication

Clobazam, sold under the brand names Frisium, Onfi and others, is a benzodiazepine class medication that was patented in 1968. Clobazam was first synthesized in 1966 and first published in 1969. Clobazam was originally marketed as an anxioselective anxiolytic since 1970, and an anticonvulsant since 1984. The primary drug-development goal was to provide greater anxiolytic, anti-obsessive efficacy with fewer benzodiazepine-related side effects.

<span class="mw-page-title-main">Fetal hydantoin syndrome</span> Medical condition

Fetal hydantoin syndrome, also called fetal dilantin syndrome, is a group of defects caused to the developing fetus by exposure to teratogenic effects of phenytoin. Dilantin is the brand name of the drug phenytoin sodium in the United States, commonly used in the treatment of epilepsy.

<span class="mw-page-title-main">Lacosamide</span> Anticonvulsant and analgesic medication

Lacosamide, sold under the brand name Vimpat among others, is a medication used for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures. It is used by mouth or intravenously.

<span class="mw-page-title-main">Perampanel</span> Anti-epileptic medication

Perampanel, sold under the brand name Fycompa, is an anti-epileptic medication developed by Eisai Co. that is used in addition to other drugs to treat partial seizures and generalized tonic-clonic seizures for people older than twelve years. It was first approved in 2012, and as of 2016, its optimal role in the treatment of epilepsy relative to other drugs was not clear. It was the first antiepileptic drug in the class of selective non-competitive antagonist of AMPA receptors.

Women with epilepsy can have safe, healthy pregnancies and healthy babies. However, proper planning and care is essential. The goal of planning is to minimize the risk of congenital malformations and neurodevelopmental disorders for the fetus while maintaining the mother's seizure control.

References

  1. 1 2 3 "International trade names for phenytoin". Drugs.com. Archived from the original on 23 February 2016. Retrieved 27 February 2016.
  2. ↑ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 "Phenytoin". The American Society of Health-System Pharmacists. Archived from the original on 8 September 2015. Retrieved 22 August 2015.
  4. 1 2 3 Marx JA (2010). Rosen's emergency medicine: concepts and clinical practice (7th ed.). Philadelphia: Mosby/Elsevier. p. 1352. ISBN   9780323054720.
  5. ↑ Parker KD, Elliott HW, Wright JA, Nomof N, Hine CH (March 1970). "Blood and urine concentrations of subjects receiving barbiturates, meprobamate, glutethimide, or diphenylhydantoin". Clinical Toxicology. 3 (1). Informa UK Limited: 131–145. doi:10.3109/15563657008990108. PMID   5520387.
  6. ↑ Aicardi J (2008). Epilepsy : a comprehensive textbook (2nd ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 1431. ISBN   9780781757775.
  7. ↑ Wolfson AB (2010). Harwood-Nuss' clinical practice of emergency medicine (5th ed.). Philadelphia, PA: Lippincott Williams & Wilkins. p. 1415. ISBN   9780781789431 . Retrieved 9 June 2016.
  8. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  9. 1 2 Hamilton RJ (2013). Tarascon pocket pharmacopoeia (14 ed.). Burlington, MA.: Jones & Bartlett Learning. p. 294. ISBN   9781449673635.
  10. ↑ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
  11. ↑ "Phenytoin - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
  12. ↑ Joiner EF, Youngerman BE, Hudson TS, Yang J, Welch MR, McKhann GM, et al. (April 2018). "Effectiveness of perioperative antiepileptic drug prophylaxis for early and late seizures following oncologic neurosurgery: a meta-analysis". Journal of Neurosurgery. 130 (4): 1274–1282. doi: 10.3171/2017.10.JNS172236 . PMID   29701546.
  13. ↑ "Phenytoin". Lexi-Comp Online. Archived from the original on 4 March 2016. Retrieved 18 April 2014.
  14. ↑ Treadwell JR, Wu M, Tsou AY (2022). "Management of Infantile Epilepsies". AHRQ Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US). doi:10.23970/ahrqepccer252. PMID   36383706. S2CID   254357105. Report No.: 22(23)-EHC004 2021-SR-01.
  15. ↑ McEvoy GK, Miller J, Snow EK (2004). AHFS Drug Information 2004. American Society of Health-System Pharmacists. pp. 2117–2120. ISBN   9781590742495.
  16. ↑ Satoskar RS, Rege NB, Bhandarkar SD (2011). Pharmacology and Pharmacotherapeutics (22nd ed.). Popular Prakashan Ltd. p. 219. ISBN   9788179916582.
  17. 1 2 3 4 Phenytoin [package insert]. New York, NY: Pfizer Inc.; 2013. Accessed 2 November 2014.
  18. 1 2 3 "Parenteral Dilantin (Phenytoin Sodium Injection, USP)" (PDF). Parke-Davis. U.S. Food and Drug Administration. October 2011. Archived (PDF) from the original on 19 April 2014. Retrieved 18 April 2014.
  19. ↑ "Dilantin Toxicity". Family Practice Notebook, LLC. Archived from the original on 19 April 2014.
  20. ↑ De Marcos FA, Ghizoni E, Kobayashi E, Li LM, Cendes F (July 2003). "Cerebellar volume and long-term use of phenytoin". Seizure. 12 (5): 312–315. doi: 10.1016/s1059-1311(02)00267-4 . PMID   12810345.
  21. ↑ Donofrio PD (2012). "Medicine Related Neuropathy". In Donofrio PD (ed.). Textbook of Peripheral Neuropathy. New York: Demos Medical Publishing. p. 208. ISBN   978-1-936287-10-9.
  22. ↑ Carl GF, Smith ML (1992). "Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin". Epilepsia. 33 (2): 372–375. doi:10.1111/j.1528-1157.1992.tb02330.x. PMID   1547769. S2CID   40927589.
  23. ↑ Sharafuddin MJ, Spanheimer RG, McClune GL (1991). "Phenytoin-induced agranulocytosis: a nonimmunologic idiosyncratic reaction?". Acta Haematologica. 86 (4): 212–213. doi:10.1159/000204838. PMID   1805490.
  24. ↑ Handoko KB, Souverein PC, van Staa TP, Meyboom RH, Leufkens HG, Egberts TC, et al. (July 2006). "Risk of aplastic anemia in patients using antiepileptic drugs". Epilepsia. 47 (7): 1232–1236. doi:10.1111/j.1528-1167.2006.00596.x. hdl: 1874/27341 . PMID   16886988. S2CID   25327883.
  25. ↑ Workman ML, Lacharity LA (2016). Understanding Pharmacology: Essentials for Medication Safety (2nd ed.). St. Louis, Missouri: Elsevier Health Sciences. ISBN   978-1-4557-3976-9.
  26. ↑ Hamblin TJ (August 2005). "Aplastic anaemia". NetDoctor. Archived from the original on 12 February 2013. Retrieved 8 July 2013.
  27. 1 2 3 Bromley R, Weston J, Adab N, Greenhalgh J, Sanniti A, McKay AJ, et al. (Cochrane Epilepsy Group) (October 2014). "Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child". The Cochrane Database of Systematic Reviews. 2014 (10): CD010236. doi:10.1002/14651858.CD010236.pub2. PMC   7390020 . PMID   25354543.
  28. 1 2 3 Bromley R, Adab N, Bluett-Duncan M, Clayton-Smith J, Christensen J, Edwards K, et al. (August 2023). "Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child". The Cochrane Database of Systematic Reviews. 2023 (8): CD010224. doi:10.1002/14651858.CD010224.pub3. PMC   10463554 . PMID   37647086.
  29. ↑ Beckmann CR, et al. (2002). Obstetrics and Gynecology (4th ed.). Baltimore: Lippincott Williams & Wilkins.
  30. ↑ National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect (July 2004). "Fetal Alcohol Syndrome: Guidelines for Referral and Diagnosis" (PDF). National Center on Birth Defects and Developmental Disabilities. Centers for Disease Control and Prevention; U.S. Department of Health and Human Services.
  31. ↑ Report on Carcinogens, Eleventh Edition (PB2005-104914, 2004) p III-216.
  32. ↑ Maeda T, Sano N, Togei K, Shibata M, Izumi K, Otsuka H (1988). "Lack of carcinogenicity of phenytoin in (C57BL/6 x C3H)F1 mice". Journal of Toxicology and Environmental Health. 24 (1): 111–119. doi:10.1080/15287398809531144. PMID   3373561.
  33. ↑ Schwinghammer TL, Howrie DL (June 1983). "Phenytoin-induced lymphadenopathy". Drug Intelligence & Clinical Pharmacy. 17 (6): 460–462. doi:10.1177/106002808301700608. PMID   6861635. S2CID   37504937.
  34. ↑ Arya R, Gulati S, Kabra M, Sahu JK, Kalra V (April 2011). "Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children". Neurology. 76 (15): 1338–1343. doi:10.1212/WNL.0b013e3182152844. PMC   3090066 . PMID   21482950.
  35. ↑ Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, et al. (May 2007). "Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese". Epilepsia. 48 (5): 1015–1018. doi: 10.1111/j.1528-1167.2007.01022.x . PMID   17509004. S2CID   34728720.
  36. ↑ Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, et al. (November 2014). "Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing". Clinical Pharmacology and Therapeutics. 96 (5): 542–548. doi:10.1038/clpt.2014.159. PMC   4206662 . PMID   25099164.
  37. ↑ "DILANTIN- phenytoin sodium capsule, extended release". Archived from the original on 2 April 2015. Retrieved 12 March 2015.
  38. ↑ Scheinfeld N (August 2003). "Phenytoin in cutaneous medicine: its uses, mechanisms and side effects". Dermatology Online Journal. 9 (3): 6. doi:10.5070/D32197W4T4. PMID   12952753. Archived from the original on 29 August 2008.
  39. ↑ Gilhus NE, Aarli JA (1981). "The reversibility of phenytoin-induced IgA deficiency". Journal of Neurology. 226 (1): 53–61. doi:10.1007/BF00313318. PMID   6181216. S2CID   23984720.
  40. ↑ Cuttle L, Munns AJ, Hogg NA, Scott JR, Hooper WD, Dickinson RG, et al. (August 2000). "Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation". Drug Metabolism and Disposition. 28 (8): 945–950. PMID   10901705.
  41. ↑ Carter BL, Garnett WR, Pellock JM, Stratton MA, Howell JR (1981). "Effect of antacids on phenytoin bioavailability". Therapeutic Drug Monitoring. 3 (4): 333–340. doi:10.1097/00007691-198104000-00003. PMID   7336470. S2CID   26099092.
  42. ↑ "Lexi-Comp Online Interaction Lookup". Lexi-Comp. Archived from the original on 19 April 2014.
  43. ↑ Rogawski MA, Löscher W (July 2004). "The neurobiology of antiepileptic drugs". Nature Reviews. Neuroscience. 5 (7): 553–564. doi:10.1038/nrn1430. PMID   15208697. S2CID   2201038.
  44. ↑ lippincots modern pharmacology with clinical applications pg no:377 5th Edition
  45. ↑ "Dilantin". MIMS. 2015. Archived from the original on 10 August 2014.
  46. ↑ Alarcon G, Antonio V, eds. (2012). Introduction to Epilepsy. Cambridge University Press. doi:10.1017/CBO9781139103992. ISBN   9781139103992. Archived from the original on 25 September 2020. Retrieved 17 January 2013.
  47. ↑ Patsalos PN (2012). "Chapter 67 Antiepileptic drug pharmacokinetics and therapeutic drug monitoring". Antiepileptic drug pharmacokinetics and therapeutic drug monitoring. Cambridge University Press. pp. 358–366.
  48. ↑ "PNYFR - Clinical: Phenytoin, Total and Free, Serum". Archived from the original on 1 March 2013. Retrieved 17 January 2013.
  49. ↑ Donahue S, Flockhart DA, Abernethy DR (December 1999). "Ticlopidine inhibits phenytoin clearance". Clinical Pharmacology and Therapeutics. 66 (6): 563–568. doi:10.1053/cp.1999.v66.103277001. PMID   10613611. S2CID   25980868.
  50. ↑ Biltz H (1908). "Über die Konstitution der Einwirkungsprodukte von substituierten Harnstoffen auf Benzil und über einige neue Methoden zur Darstellung der 5,5-Diphenyl-hydantoine" [Constitution of the Products of the Interaction of Substituted Carbamides on Benzil and Certain New Methods for the Preparation of 5,5-Diphenylhydantoin]. Chemische Berichte (in German). 41 (1): 1379–1393. doi:10.1002/cber.190804101255.
  51. ↑ Friedlander WJ (1986). "Putnam, Merritt, and the discovery of Dilantin". Epilepsia. 27 (Suppl 3): S1-20. doi:10.1111/j.1528-1157.1986.tb05743.x. PMID   3527690. S2CID   7761284.
  52. ↑ Goodman and Gilman's Pharmacological Basis of Therapeutics (10th ed.). New York: McGraw-Hill. 2001.
  53. ↑ Stout D (31 August 2000). "2 Nixon Aides Skeptical About Report That He Took Drug". The New York Times . Retrieved 6 February 2020.
  54. ↑ Campbell J (6 January 2006). Muir D (ed.). "New Nixon Biography Gives Salacious Details". ABC News . New York City, New York, United States of America: American Broadcasting Company (Walt Disney Television). Retrieved 7 August 2021.
  55. ↑ Dreyfus J (1998). A Remarkable Medicine Has Been Overlooked: Including an Autobiography and the Clinical Section of the Broad Range of Use of Phenytoin . Continuum International Publishing Group. ISBN   978-0-8264-1069-6.
  56. ↑ "AERS data". FDA. Archived from the original on 19 April 2014. Retrieved 18 April 2014.
  57. ↑ "Phenytoin Sodium Flynn Hard Capsules...Marketing authorisation holder". Flynn Pharma patient information leaflet at the electronic Medicines Compendium. 24 April 2014. Archived from the original on 15 January 2017. Retrieved 13 May 2014.
  58. ↑ "Healthcare Professionals Advised That Epanutin Capsules Are Only To Be Available Under The Generic Name". Durham, NC: MediGuard. 2 October 2012. Archived from the original on 14 May 2014. Retrieved 13 May 2014.
  59. ↑ Adams S (12 October 2012). "Pharma firm hikes cost of epilepsy drug 24 times". Daily Telegraph. London. Archived from the original on 13 October 2012. Retrieved 13 May 2014.
  60. ↑ Gould M (21 November 2012). "Price of anti-epilepsy drug rockets". Pulse. London. Archived from the original on 28 November 2012. Retrieved 13 May 2014.
  61. ↑ White M (12 August 2015). "Pharma market abuse isn't picked up fast enough". Health Service Journal. Archived from the original on 7 October 2015. Retrieved 6 October 2015.
  62. ↑ "CMA fines Pfizer and Flynn £90 million for drug price hike to NHS" (Press release). www.gov.uk. Archived from the original on 7 December 2016. Retrieved 7 December 2016.
  63. ↑ "Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan". Pfizer. 16 November 2020. Retrieved 17 June 2024– via Business Wire.
  64. ↑ "Dilantin". Pfizer. Retrieved 17 June 2024.
  65. ↑ "Brands". Viatris. 16 November 2020. Retrieved 17 June 2024.
  66. ↑ Shaw J, Hughes CM, Lagan KM, Bell PM (November 2007). "The clinical effect of topical phenytoin on wound healing: a systematic review". The British Journal of Dermatology. 157 (5): 997–1004. doi:10.1111/j.1365-2133.2007.08160.x. PMID   17854378. S2CID   23862219.
  67. ↑ Bhatia A, Prakash S (July 2004). "Topical phenytoin for wound healing". Dermatology Online Journal. 10 (1): 5. doi:10.5070/D30Z3612W1. PMID   15347487.
  68. ↑ Thangaraju P, Tamilselvan T, Venkatesan S, Eswaran T, Singh H, Giri VC, et al. (July 2015). "Topical Phenytoin for Managing Various Ulcers:A meta-analysis". Sudan Medical Monitor. 10 (2): 63–67. doi: 10.4103/1858-5000.160951 . S2CID   74076946.
  69. ↑ Riepl M (2022). "A Compendium of Compounding Agents and Formulations, Part 6: Additional Preparations for Refractory Dermal-wound Healing". International Journal of Pharmaceutical Compounding. 26 (6): 480–488. PMID   36445767.
  70. ↑ Banov D, Song G, Foraida Z, Tkachova O, Zdoryk O, Carvalho M (2024). "Integrated In Vivo and In Vitro Evaluation of a Powder-to-Hydrogel, Film-Forming Polymer Complex Base with Tissue-Protective and Microbiome-Supportive Properties". Gels. 10 (7): 447. doi: 10.3390/gels10070447 . ISSN   2310-2861. PMC   11276563 . PMID   39057470.
  71. ↑ Raftopoulos R, Hickman SJ, Toosy A, Sharrack B, Mallik S, Paling D, et al. (March 2016). "Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial". The Lancet. Neurology. 15 (3): 259–269. doi: 10.1016/S1474-4422(16)00004-1 . PMID   26822749. S2CID   38835886.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.